Maluf D G, Dumur C I, Suh J L, Lee J K, Cathro E P, King A L, Gallon L, Brayman K L, Mas V R
University of Virginia, Department of Surgery PO Box 800679, Charlottesville, VA 22908-0679.
University of Virginia, Department of Pathology PO Box 800904, VA 22908-0214.
Am J Transplant. 2014 May;14(5):1152-1163. doi: 10.1111/ajt.12696. Epub 2014 Apr 2.
The molecular basis of calcineurin inhibitor toxicity (CNIT) in kidney transplantation (KT) and its contribution to chronic allograft dysfunction (CAD) with interstitial fibrosis (IF) and tubular atrophy (TA) were evaluated by: (1) identifying specific CNIT molecular pathways that associate with allograft injury (cross-sectional study) and (2) assessing the contribution of the identified CNIT signature in the progression to CAD with IF/TA (longitudinal study). Kidney biopsies from well-selected transplant recipients with histological diagnosis of CNIT (n = 14), acute rejection (n = 13) and CAD with IF/TA (n = 10) were evaluated. Normal allografts (n = 18) were used as controls. To test CNIT contribution to CAD progression, an independent set of biopsies (n = 122) from 61 KT patients collected at 3 and ~12 months post-KT (range = 9-18) were evaluated. Patients were classified based on 2-year post-KT graft function and histological findings as progressors (n = 30) or nonprogressors to CAD (n = 31). Molecular signatures characterizing CNIT samples were identified. Patients classified as progressors showed an overlap of 7% and 22% with the CNIT signature at 3 and at ~12 months post-KT, respectively, while the overlap was <1% and 1% in nonprogressor patients, showing CNIT at the molecular level as a nonimmunological factor involved in the progression to CAD.
通过以下方式评估肾移植(KT)中钙调神经磷酸酶抑制剂毒性(CNIT)的分子基础及其对伴有间质纤维化(IF)和肾小管萎缩(TA)的慢性移植肾功能障碍(CAD)的影响:(1)识别与移植肾损伤相关的特定CNIT分子途径(横断面研究),以及(2)评估所识别的CNIT特征在IF/TA导致CAD进展过程中的作用(纵向研究)。对精心挑选的、经组织学诊断为CNIT(n = 14)、急性排斥反应(n = 13)和伴有IF/TA的CAD(n = 10)的移植受者的肾活检组织进行评估。正常移植肾(n = 18)用作对照。为了测试CNIT对CAD进展的作用,对61例KT患者在KT后3个月和12个月(范围 = 9 - 18)收集的一组独立活检组织(n = 122)进行评估。根据KT后2年的移植肾功能和组织学结果将患者分为CAD进展者(n = 30)或非进展者(n = 31)。识别出表征CNIT样本的分子特征。分类为进展者的患者在KT后3个月和12个月时与CNIT特征的重叠率分别为7%和22%,而非进展者患者的重叠率分别<1%和<1%,这表明在分子水平上CNIT是参与CAD进展的非免疫因素。